Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
Price : $35 *
At a glance
- Drugs Risperidone (Primary)
- Indications Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia; Substance-related disorders
- Focus Pharmacodynamics
- 17 Aug 2016 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 26 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.